Etoricoxib in Ear Nose Throat Surgery

Summary

The aim of this study is to test the analgesic efficacy of etoricoxib (90 mg or 120 mg qd. perioperatively) for post-operative pain relief. The primary endpoint is as follows: * does preoperative etoricoxib reduce the post-operative opioid utilization in patients undergoing elective tonsillectomy under general anaesthesia (i.e. the post-operative opioid-sparing effect of etoricoxib in humans). The secondary endpoints are as follows: * does the etoricoxib medication have an impact on PONV or activities of daily * does the etoricoxib medication influence the blood loss during surgery or the incidence of postoperative bleeding * does the etoricoxib medication influence the operation time. In addition, adverse effects of etoricoxib will be documented.

Timeline

Start

2008-10

Primary completion

2009-09

Completion

2009-12

Drugs

Indications

No indication recorded.